- Home
- GDYN vs AVBP Comparison
GDYN vs AVBP Comparison
Compare GDYN & AVBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDYN
- AVBP
- Stock Information
- Founded
- GDYN 2006
- AVBP 2021
- Country
- GDYN United States
- AVBP United States
- Employees
- GDYN N/A
- AVBP N/A
- Industry
- GDYN Computer Software: Prepackaged Software
- AVBP
- Sector
- GDYN Technology
- AVBP
- Exchange
- GDYN Nasdaq
- AVBP NYSE
- Market Cap
- GDYN 1.1B
- AVBP 862.8M
- IPO Year
- GDYN N/A
- AVBP 2024
- Fundamental
- Price
- GDYN $10.46
- AVBP $21.87
- Analyst Decision
- GDYN Strong Buy
- AVBP Strong Buy
- Analyst Count
- GDYN 4
- AVBP 8
- Target Price
- GDYN $18.75
- AVBP $38.38
- AVG Volume (30 Days)
- GDYN 744.0K
- AVBP 457.5K
- Earning Date
- GDYN 07-31-2025
- AVBP 08-13-2025
- Dividend Yield
- GDYN N/A
- AVBP N/A
- EPS Growth
- GDYN 322.00
- AVBP N/A
- EPS
- GDYN 0.13
- AVBP N/A
- Revenue
- GDYN $371,169,000.00
- AVBP N/A
- Revenue This Year
- GDYN $21.02
- AVBP $85.82
- Revenue Next Year
- GDYN $13.95
- AVBP N/A
- P/E Ratio
- GDYN $83.04
- AVBP N/A
- Revenue Growth
- GDYN 18.72
- AVBP N/A
- 52 Week Low
- GDYN $10.37
- AVBP $15.47
- 52 Week High
- GDYN $25.50
- AVBP $36.37
- Technical
- Relative Strength Index (RSI)
- GDYN 27.92
- AVBP 49.36
- Support Level
- GDYN $11.48
- AVBP $19.71
- Resistance Level
- GDYN $12.86
- AVBP $22.32
- Average True Range (ATR)
- GDYN 0.53
- AVBP 1.11
- MACD
- GDYN -0.07
- AVBP -0.13
- Stochastic Oscillator
- GDYN 4.38
- AVBP 50.00
About GDYN Grid Dynamics Holdings Inc.
Grid Dynamics Holdings Inc is a provider of technology consulting, platform and product engineering, and advanced analytics services. The company delivers tailored solutions in several industry verticals like Tech, Media and Telecom, Retail, Finance and Consumer Packaged goods (CPG)/manufacturing. The company derives maximum revenue from Retails. Geographically company earns revenue from North America, Europe and other regions.
About AVBP ARRIVENT BIOPHARMA INC
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.